NEVVI Medicare utilization intelligence
Compare this code with others

Jump to the result views

G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test HCPCS · Molecular Testing
Classification Test › Molecular Testing › Infectious Agent Detection by DNA/RNA (CMS RBCS)
First observed 2015
National scale 24,304 services · est. ▲ 1.5% YoY · 11,809 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 11,809 observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window · National figures — the TN market is below
Data year CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Filter results:
Market summary
Market Brief G0476
A shareable PDF report summarizing this market’s size, trends, and providers.
Preview this Brief →

This market's Overview — its estimated all-Medicare volume, national benchmarks, and what the field charges and is paid — is part of Explore.

See what Medicare pays

An Explore subscription, $249 a seat a year, opens the Overview on every code, group and clinician page, including what the market charges and is paid.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →

Included in Explore. Part of a Deep Dive.
Continue from here